The Current Market for Chemotherapies is Estimated at US$42 Billion and is Forecast to Increase Approximately 17% to US$49 Billion by 2012.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c36303) has announced the addition of the new Spectra Intelligence report "Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities" to their offering In a market currently valued around US$42 billion, cancer chemotherapies are on course for staggering growth potential and may revolutionize cancer treatments over the next 10 years according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. a new report from biopharma market research publisher, Spectra Intelligence. "The chemotherapy market is currently the fastest growing in the pharmaceutical industry, driven by the explosion of potential therapeutic targets revealed by the molecular genetic assessments of cancer biology and fuelled by the magnitude of the disease worldwide, which shows every indication of increased incidence and sustained mortality rates over the next decade" says expert report author Dr Sarah Crawford PhD, Associate Professor of Biology and Director of Experimental Chemotherapy at Southern Connecticut State University  This article or section is written like an .Please help [ rewrite this article] from a neutral point of view. Mark blatant advertising for , using . , USA. With more than 25 million people affected by cancer globally, and an estimated 5 million people dying each year as a result of cancer, new treatments are clearly needed to curtail these high mortality statistics despite the availability of effective cancer drugs such as Herceptin and Avastin. Dr Crawford cautions however that although there are very exciting and promising novel cancer therapeutics on the horizon with limitless potential, enthusiasm must be tempered by the need to identify those chemotherapy approaches that may have the greatest potential for therapeutic success and suggests that there is a need to distinguish important new entries to the cancer therapeutics market from those therapy approaches that may not fare as well on the world market. Biopharmaceutical industry analyst Tim Atkinson, who reviewed the report, said "Dr Crawford has provided an exceptionally comprehensive first-rate analysis of our current understanding of cancer biology, cancer treatment approaches, diagnosis and management, and hopes for the future given the complexity and heterogeneity of this devastating dev·as·tate tr.v. dev·as·tat·ed, dev·as·tat·ing, dev·as·tates 1. To lay waste; destroy. 2. To overwhelm; confound; stun: was devastated by the rude remark. disease. The report uniquely highlights the deficiencies and possibilities of cancer research and cancer drug development, which will undoubtedly help to create significant market opportunities and change the landscape for cancer treatments in the future." Dr Crawford adds "The world of molecular medicine and biopharmaceuticals has presented great opportunities to discover and develop new pharmacological approaches with prospects for greater therapeutic efficacy and more promising clinical outcomes. Immunotherapies, monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). , new reformulations, and multimodal Two or more modes of operation. The term is used to refer to a myriad of functions and conditions in which two or more different methods, processes or forms of delivery are used. On the Web, it refers to asking for something one way and receiving the answer another; for example requesting chemotherapy treatment regimens that combined with an ever-evolving understanding of the intricacies of cancer and the identification of new potential cell targets, will be the some of the new weapons in our fight against cancer". This new report from Spectra Intelligence, "Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities", provides an in-depth assessment and analysis of the global cancer therapy market. Included in this study are critical analyses of key therapeutic areas, epidemiological, aetiological AE`ti`o`log´ic`al a. 1. Pertaining to ætiology; assigning a cause. Adj. 1. aetiological - of or relating to the philosophical study of causation aetiologic, etiologic, etiological 2. , and healthcare data, R&D programs, and innovating companies and products. The reader will benefit from authoritative critical review, market forecasts to 2016, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate research and industrial growth, and create new market opportunities. Report Highlights and Key Findings - The current market for chemotherapies is estimated at US$42 billion and is forecast to increase approximately 17% to US$49 billion by 2012 - Critical assessment of the challenges to the development of better, more efficacious cancer treatments with fewer side effects Side effects Effects of a proposed project on other parts of the firm. - Analysis of the problems associated with the use of traditional cancer therapeutics, e.g. drug resistance, lack of clinical efficacy, side effects - Focused analysis of the global prevalence of cancer: incidence, mortality and survival rates as they relate to new directions in cancer research - Identification of the major classes of cancer drugs currently in research and development using the newest technologies and genetic approaches - Highlights the most successful cancer therapeutics that may serve as prototypes for the research and development of more effective drugs - Market analysis of trends in the cancer biotech industry to 2016 - Concise product review data for the most innovative and productive biopharmaceutical companies - Assessment of all recent clinical trial data for investigational cancer drugs and prospects for approval by regulatory agencies - Comparative assessment of new drugs with similar therapeutic targets - Assessment of the newest clinical approaches to the treatment of cancer Companies mentioned: - Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals and health care company. It has over 65,000 employees and operates in 130 countries. The corporate headquarters are in Abbott Park, Illinois, a neighborhood of North Chicago, Illinois. - Access Pharma - Adventrix Pharma - Aegera Therapeutics - Akzo Nobel Akzo Nobel is a multinational company, active in the fields of healthcare products, coatings and chemicals. Headquartered in Amsterdam, the Netherlands, the company has activities in more than 80 countries, and employs approximately 62,000 people. - Alcon Laboratories - Allergan - Altana - Altus Pharm - Amgen - Antigenics - Antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). Pharma - Antisoma - Aphton - Ariad Pharma - Arqule - Astrazeneca - Avalon Pharma - Avax Technologies - Avidex - Baxter International Baxter International Inc. (NYSE: BAX), is a global healthcare company with 48,000 employees and 2006 sales of US$10.4 billion. Its headquarters is in Deerfield, Illinois. - Bayer - Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec - Bionumerik Pharm - Biotica - Biovest International - Boehringer-Ingelheim - Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were - Callisto Pharma - Caprion Pharm - Celgene - Cell Genesys - Cell Therapeutics - Chemgenex Pharm - Chugai - Chiron - Coley coley Noun Brit an edible fish with white or grey flesh [perhaps from coalfish] Pharma - Conforma - Dynavax Technology Corp - Ecopia Pharmaceutical Company - Eisai - Eli Lilly Eli Lilly can refer to:
- Enzon Pharma - Ercole - Eximias Pharma - Forest Labs - Fujisawa - Genaera - Genentech - Genitope Corp - Genzyme - Geron Pharmaceuticals - Glaxosmithkline - Gpc Biotech GPC Biotech (also referred to as GPCbiotech and GPC-Biotech) is a German biopharmaceutical company. The company's mission statement reads "... to discover, develop and commercialize new anticancer drugs. - Helix Biopharma - Hybridon - Idera Pharma - Idun Pharma - Imclone Systems ImClone Systems Incorporated (NASDAQ: IMCL) is a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology. It was founded in 1984 and is headquartered in New York City. It is traded on the NASDAQ stock exchange under the symbol IMCL. - Immunogen - Immusol - Inex Pharma - Infinity Pharma - Inovio - Isis Pharma - Ivax - Johnson & Johnson - King Pharmaceuticals King Pharmaceuticals (NYSE: KG), the world's 39th largest pharmaceutical company, is based in Bristol, Tennessee.[1][2] King produces a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a - Kosan Biosciences - Ligand Pharma - Light Sciences - Lundbeck - Maxim Pharma - Medarex - Medigene - Medimmune - Merck & Co. - Milagen - Millennium Pharmaceuticals Millennium Pharmaceuticals NASDAQ: MLNM is a biotechnology company based in the Cambridge, Massachusetts area of the United States of America. Founded in 1993, the company conducts research in various scientific areas, currently focusing on inflammation and oncology. - Mitsubishi Pharma - Morphosys - Mylan Labs - Neorx - Novartis - Novo Nordisk - Oncogenix - Oncolytics Biotech - Ono - Onyx Pharma - Organon or·ga·non or or·ga·num n. pl. or·ga·nons or or·ga·nums or or·ga·na 1. An organ. 2. A set of principles for use in scientific investigation. organon pl. organa [Gr.] organ. - Ortho Biotech - Osi Pharma - Otsuka - Panacea Pharma - Penegrine Pharma - Pfizer - Prolexys Pharma - Protherics - Provectus Pharma - Purdue Pharma - Quark Biotech - Receptor Biologix - Regeneron Pharmaceuticals - Roche - Sankyo - Sanofi-Aventis - Schering Ag - Schering-Plough - Semafore Pharma - Serono - Sgx Pharma - Shionogi Seiyaku - Shire - Solvay - Spectrum Pharma - Starpharmasunesis Pharma - Synta Pharma - Syrrx - Takeda - Tanabe Seiyaku - Tap Pharmaceutical - Tapestry Pharma - Teva - Therion Biologics - Transgene transgene a gene that has been incorporated into the genome of another organism. - U3 Pharma - Ucb - Vaxon Biotech - Vertex Pharmaceuticals - Vion Pharma - Viventia Biotech - Watson - Wyeth - Xoma - Yamanouchi - Ym Biosciences - Zymo Genetics For more information visit http://www.researchandmarkets.com/reports/c36303 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion